Association of gene variants with lipid levels in response to fenofibrate is influenced by metabolic syndrome status.

ABSTRACT:

Objective

Fenofibrate therapy reduces serum triglycerides (TG) and increases high-density lipoprotein-cholesterol (HDL-C) and thus addresses the atherogenic dyslipidemia associated with metabolic syndrome (MetS). Our hypothesis is that genetic factors contribute to the variability of lipid response to fenofibrate differently in subjects with MetS and without MetS.

Methods

We investigated the association in 25 candidate genes with lipid responses to a 3-weeks trial on fenofibrate in subjects with and without MetS. We employed growth curve mixed models to generate the response phenotypes to fenofibrate in TG, HDL-C, and low-density lipoprotein-cholesterol (LDL-C) and examined the genetic associations accounting for family dependencies.

Results

After correcting for multi

SUBMITTER: Feitosa MF 

PROVIDER: S-EPMC3777277 | biostudies-literature | 2011 Apr

REPOSITORIES: biostudies-literature